Infection and Atherosclerosis

Infection and Autoimmunity, 2nd edition

Volumn , Issue , 2004, Pages 701-709

  Frostegrd, Johan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 32544440737     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-044451271-0.50055-7     Document Type: Chapter

References (85)

1. Frostegrd J, Ulfgren AK, Nyberg P, Hedin U, Swedenborg J, Andersson U, Hansson GK Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 1999, 145:33-43.
2. Jonasson L, Holm J, Skalli O, Bondjers G, Hansson GK Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis 1986, 6:131-138.
3. Ross R Atherosclerosis-an inflammatory disease. N Engl J Med 1999, 340:115-126.
4. Ridker PM, Hennekens CH, Buring JE, Rifai N Creactive protein and other markers of infammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342:836-843.
5. Svenungsson E, Jensen-Urstad K, heimburger M, Silveira A, Hamsten A, de Faire U, Witztum JL, Frostegrard J Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001, 104:1887-1893.
6. Svenungsson E, Fei GZ, Jensen-Urstad K, de Faire U, Hamsten A, Frostegard J TNF-alpha: a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease. Lupus 2003, 12:454-461.
7. Shoenfeld Y, Sherer Y, Harats D Artherosclerosis as an infectious, inflammatory and autoimmune disease. Trends Immunol 2001, 22:293-295.
8. Wick G, Perschinka H, Millonig G Atherosclerosis as an autoimmune disease: an update. Trends Immunol 2001, 22:665-669.
9. Binder CJ, Chang MK, Shaw PX, Miller YI, Hartvigsen K, Dewan A, Witztum JL Innate and acquired immunity in atherogenesis. Nat Med 2002, 8:1218-1226.
10. Frostegard J, Kjellman B, Gidlund M, Andersson B, Jindal S, Kiessling R Induction of heat shock protein in monocytic cells by oxidized low density lipoprotein. Atherosclerosis 1996, 121:93-103.
11. Meier CR, Jick SS, Derby LE, Vasilakis C, Jick H Acute respiratory-tract infections and risk of firsttime acute myocardial infarction. Lancet 1998, 351:1467-1471.
12. Kalayoglu MV, Libby P, Byrne GI Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. Jama 2002, 288:2724-2731.
13. Saikku P, Leinonen M, Mattila K, Ekman MR, Nieminen MS, Makela PH, Huttunen JK, Valtonen V Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988, 2:983-986.
14. Danesh J, Whincup P, Walker M Chlamydia pneumoniae IgA titres and coronary heart disease: prospective study and meta-analysis. Eur Heart J 2003, 24:881.
15. Huittinen T, Leinonen M, Tenkanen L, Virkkunen H, Manttari M, Palosuo T, Manninen V, Saikku P Synergistic effect of persistent Chlamydia pneumoniae infection, autoimmunity, and inflammation on coronary risk. Circulation 2003, 107:2566-2570.
16. Thomas M, Wong Y, Thomas D, Ajaz M, Tsang V, Gallagher PJ, Ward ME Relation between direct detection of Chlamydia pneumoniae DNA in human coronary arteries at postmortem examination and histological severity (Stary grading) of associated atherosclerotic plaque. Circulation 1999, 99:2733-2736.
17. Davidson M, Kuo CC, Middaugh JP, Campbell LA, Wang SP, Newman WP, Finley JC, Grayston JT Confirmed previous infection with Chlamydia pneumoniae (TWAR) and its presence in early coronary atherosclerosis. Circulation 1998, 98:628-633.
18. Kalayoglu MV, Byrne GI Induction of macrophage foam cell formation by Chlamydia pneumoniae. J Infect Dis 1998, 177:725-729.
19. Kalayoglu MV, Hoerneman B, LaVerda D, Morrison SG, Morrison RP, Byrne GI Cellular oxidation of lowdensity lipoprotein by Chlamydia pneumoniae. J Infect Dis 1999, 180:780-790.
20. Bulut Y, Faure E, Thomas L, Karahashi H, Michelsen KS, Equils O, Morrison SG, Morrison RP, Arditi M Chlamydial heat shock protein 60 activates macrophages and endothelial cells through Toll-like receptor 4 and MD2 in a MyD88-dependent pathway. J Immunol 2002, 168:1435-1440.
21. Blessing E, Nagano S, Campbell LA, Rosenfeld ME, Kuo CC Effect of Chlamydia trachomatis infection on atherosclerosis in apolipoprotein E-deficient mice. Infect Immun 2000, 68:7195-7197.
22. Campbell LA, Blessing E, Rosenfeld M, Lin T, Kuo C Mouse models of C. pneumoniae infection and atherosclerosis. J Infect Dis 2000, 181(Suppl 3):S508-S513.
23. Caligiuri G, Rottenberg M, Nicoletti A, Wigzell H, Hansson GK Chlamydia pneumoniae infection does not induce or modify atherosclerosis in mice. Circulation 2001, 103:2834-2838.
24. Gieffers J, Fullgraf H, Jahn J, Klinger M, Dalhoff K, Katus HA, Solbach W, Maass M Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation 2001, 103:351-356.
25. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. ROXIS Study Group. Lancet 1997, 350:404-407.
26. Gabay MP, Jain R Role of antibiotics for the prevention of cardiovascular disease. Ann Pharmacother 2002, 36:1629-1636.
27. Sander D, Winbeck K, Klingelhofer J, Etgen T, Conrad B Reduced progresion of early carotid atherosclerosis after antibiotic treatment and Chlamydia pneumoniae seropositivity. Circulation 2002, 106:2428-2433.
28. Cercek B, Shah PK, Noc M, Zahger D, Zeymer U, Matetzky S, Maurer G, Mahrer P Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial. Lancet 2003, 361:809-813.
29. Brassard P, Bourgault C, Brophy J, Kezouh A, Suissa S Antibiotics in primary prevention of stroke in the elderly. Stroke 2003, 34:e163-e166.
30. Ridker PM, Hennekens CH, Stampfer MJ, Wang F Prospective study of herpes simplex virus, cytomegalovirus, and the risk of future myocardial infarction and stroke. Circulation 1998, 98:2796-2799.
31. Sorlie PD, Nieto FJ, Adam E, Folsom AR, Shahar E, Massing M A prospective study of cytomegalovirus, herpes simplex virus 1, and coronary heart disease: the atherosclerosis risk in communities (ARIC) study. Arch Intern Med 2000, 160:2027-2032.
32. Adler SP, Hur JK, Wang JB, Vetrovec GW Prior infection with cytomegalovirus is not a major risk factor for angiographically demonstrated coronary artery atherosclerosis. J Infect Dis 1998, 177:209-212.
33. O'Connor S, Taylor C, Campbell LA, Epstein S, Libby P Potential infectious etiologies of atherosclerosis: a multifactorial perspective. Emerg Infect Dis 2001, 7:780-788.
34. Grahame-Clarke C, Chan NN, Andrew D, Ridgway GL, Betteridge DJ, Emery V, Colhoun HM, Vallance P Human cytomegalovirus seropositivity is associated with impaired vascular function. Circulation 2003, 108:678-683.
35. Khairy P, Rinfret S, Tardif JC, Marchand R, Shapiro S, Brophy J, Dupuis J Absence of association between infectious agents and endothelial function in healthy young men. Circulation 2003, 107:1966-1971.
36. Bartels C, Maass M, Bein G, Brill N, Bechtel JF, Leyh R, Sievers HH Association of serology with the endovascular presence of Chlamydia pneumoniae and cytomegalovirus in coronary artery and vein graft disease. Circulation 2000, 101:137-141.
37. Weis M, von Scheidt W Cardiac allograft vasculopathy: a review. Circulation 1997, 96:2069-2077.
38. Beck J, Garcia R, Heiss G, Vokonas PS, Offenbacher S Periodontal disease and cardiovascular disease. J Periodontol 1996, 67:1123-1137.
39. Mattila KJ, Nieminen MS, Valtonen VV, Rasi VP, Kesaniemi YA, Syrjala SL, Jungell PS, Isoluoma M, Hietaniemi K, Jokinen MJ Association between dental health and acute myocardial infarction. BMJ 1989, 298:779-781.
40. DeStefano F, Anda RF, Kahn HS, Williamson DF, Russell CM Dental disease and risk of coronary heart disease and mortality. BMJ 1993, 306:688-691.
41. Beck JD, Offenbacher S, Williams R, Gibbs P, Garcia R Periodontitis: a risk factor for coronary heart disease?. Ann Periodontol 1998, 3:127-141.
42. Hujoel PP Does chronic periodontitis cause coronary heart disease? A review of the literature. J Am Dent Assoc 2002, 133(Suppl):31S-36S.
43. Buhlink, Gustafsson A, Pockley AG, Frostegrd J, Klinge B Risk factors for cardiovascular disease in patients with periodontitis. Eur Heart J 2003, 24:2099-2107.
44. Dorn BR, Dunn WA, Progulske-Fox A Invasion of human coronary artery cells by periodontal pathogens. Infect Immun 1999, 67:5792-5798.
45. Frostegard J, Huang YH, Ronnelid J, Schafer-Elinder L Platelet-activating factor and oxidized LDL induce immune activation by a common mechanism. Arterioscler Thromb Vasc Biol 1997, 17:963-968.
46. Schenkein HA, Barbour SE, Berry CR, Kipps B, Tew JG Invasion of human vascular endothelial cells by Actinobacillus actinomycetemcomitans via the receptor for platelet-activating factor. Infect Immun 2000, 68:5416-5419.
47. Meyers DG Myocardial infarction, stroke, and sudden cardiac death may be prevented by influenza vaccination. Curr Atheroscler Rep 2003, 5:146-149.
48. Maniscalco BS Shouldering the risk burden: infection, atherosclerosis, and the vascular endothelium. Circulation 2003, 107:e74.
49. Farsak B, Yildirir A, Akyon Y, Pinar A, Oc M, Boke E, Kes S, Tokgozoglu L Detection of Chlamydia pneumoniae and Helicobacter pylori DNA in human atherosclerotic plaques by PCR. J Clin Microbiol 2000, 38:4408-4411.
50. Ridker PM, Danesh J, Youngman L, Collins R, Stampfer MJ, Peto R, Hennekens CH A prospective study of Helicobacter pylori seropositivity and the risk for future myocardial infarction among socioeconomically similar US men. Ann Intern Med 2001, 135:184-188.
51. Witztum JL, Steinbrecher UP, Kesaniemi YA, Fisher M Autoantibodies to glucosylated proteins in the plasma of patients with diabetes mellitus. Proc Natl Acad Sci USA 1984, 81:3204-3208.
52. Frostegard J, Wu R, Giscombe R, Holm G, Lefvert AK, Nilsson J Induction of T-cell activation by oxidized low density lipoprotein. Arterioscler Thromb 1992, 12:461-467.
53. Huang YH, Ronnelid J, Frostegard J Oxidized LDL induces enhanced antibody formation and MHC class II-dependent IFN-gamma production in lymphocytes from healthy individuals. Arterioscler Thromb Vasc Biol 1995, 15:1577-1583.
54. Heery JM, Kozak M, Stafforini DM, Jones DA, Zimmerman GA, McIntyre TM, Prescott SM Oxidatively modified LDL contains phospholipids with platelet-activating factor-like activity and stimulates the growth of smooth muscle cells. J Clin Invest 1995, 96:2322-2330.
55. Vaarala O, Alfthan G, Jauhiainen M, Leirisalo-Repo M, Aho K, Palosuo T Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 1993, 341:923-925.
56. Shoenfeld Y, Blank M, Krause I The relationship of antiphospholipid antibodies to infections-do they bind to infecting agents or may they even be induced by them?. Clin Exp Rheumatol 2000, 18:431-432.
57. Shoenfeld Y Etiology and pathogenetic mechanisms of the anti-phospholipid syndrome unraveled. Trends Immunol 2003, 24:2-4.
58. Blank M, Krause I, Fridkin M, Keller N, Kopolovic J, Goldberg I, Tobar A, Shoenfeld Y Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest 2002, 109:797-804.
59. George J, Harats D, Gilburd B, Levy Y, Langevitz P, Shoenfeld Y Atherosclerosis-related markers in systemic lupus erythematosus patients: the role of humoral immunity in enhanced atherogenesis. Lupus 1999, 8:220-226.
60. George J, Afek A, Gilburd B, Harats D, Shoenfeld Y Autoimmunity in atherosclerosis: lessons from experimental models. Lupus 2000, 9:223-227.
61. Gharavi AE, Pierangeli SS, Espinola RG, Liu X, Colden-Stanfield M, Harris EN Antiphospholipid antibodies induced in mice by immunization with a cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo. Arthritis Rheum 2002, 46:545-552.
62. Liuba P, Persson J, Luoma J, Yla-Herttuala S, Pesonen E Acute infections in children are accompanied by oxidative modification of LDL and decrease of HDL cholesterol, and are followed by thickening of carotid intima-media. Eur Heart J 2003, 24:515-521.
63. Palinski W, Miller E, Witztum JL Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci USA 1995, 92:821-825.
64. Major AS, Fazio S, Linton MF B-lymphocyte deficiency increases atherosclerosis in LDL receptor-null mice. Arterioscler Thromb Vasc Biol 2002, 22:1892-1898.
65. Cullen P, Baetta R, Bellosta S, Bernini F, Chinetti G, Cignarella A, Von Eckardstein A, Exley A, Goddard M, Hofker M, et al. Rupture of the atherosclerotic plaque: does a good animal model exist?. Arterioscler Thromb Vasc Biol 2003, 23:535-542.
66. Wu R, de Faire U, Lemne C, Witztum JL, Frostegard J Autoantibodies to OxLDL are decreased in individuals with borderline hypertension. Hypertension 1999, 33:53-59.
67. Hulthe J, Wiklund O, Hurt-Camejo E, Bondjers G Antibodies to oxidized LDL in relation to carotid atherosclerosis, cell adhesion molecules, and phospholipase A(2). Arterioscler Thromb Vasc Biol 2001, 21:269-274.
68. Hughes G Thrombosis, abortion, cerebral disease and the lupus antikoagulant. British Medical Journal 1983, 287:1088-1089.
69. Vaarala O, Mänttäri M, Manninen V, Tenkanen L, Puurunen M, Aho KTP Anti-Cardiolipin Antibodies and Risk of Myocardial Infarction in a Prospective Cohort of Middle-Aged Men. Circulation 1995, 91:23-27.
70. Binder CJ, Horkko S, Dewan A, Chang MK, Kieu EP, Goodyear CS, Shaw PX, Palinski W, Witztum JL, Silverman GJ Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med 2003, 9:736-743.
71. Asaoka Y, Oka M, Yoshida K, Sasaki Y, Nishizuka Y Role of lysophosphatidylcholine in T-lymphocyte activation: involvement of phospholipase A2 in signal transduction through protein kinase C. Proc Natl Acad Sci USA 1992, 89:6447-6451.
72. Fortun A, Khalil A, Gagne D, Douziech N, Kuntz C, Jay-Gerin JP, Dupuis G, Fulop T Monocytes influence the fate of T cells challenged with oxidised low density lipoproteins towards apoptosis or MHC-restricted proliferation. Atherosclerosis 2001, 156:11-21.
73. Nishi E, Kume N, Ueno Y, Ochi H, Moriwaki H, Kita T Lysophosphatidylcholine enhances cytokine-induced interferon gamma expression in human T lymphocytes. Circ Res 1998, 83:508-515.
74. Farhey Y, Hess EV Accelerated atherosclerosis and coronary disease in SLE. Lupus 1997, 6:572-577.
75. Huang YH, Schafer-Elinder L, Wu R, Claesson HE, Frostegard J Lysophosphatidylcholine (LPC) induces proinflammatory cytokines by a platelet-activating factor (PAF) receptor-dependent mechanism. Clin Exp Immunol 1999, 116:326-331.
76. Fei GZ, Huang YH, Swedenborg J, Frostegard J Oxidised LDL modulates immune-activation by an IL-12 dependent mechanism. Atherosclerosis 2003, 169:77-85.
77. Shaw PX, Horkko S, Chang MK, Curtiss LK, Palinski W, Silverman GJ, Witztum JL Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity [see comments]. J Clin Invest 2000, 105:1731-1740.
78. Chang MK, Binder CJ, Torzewski M, Witztum JL C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci USA 2002, 99:13043-13048.
79. George J, Afek A, Gilburd B, Shoenfeld Y, Harats D Cellular and humoral immune responses to heat shock protein 65 are both involved in promoting fatty-streak formation in LDL-receptor deficient mice. J Am Coll Cardiol 2001, 38:900-905.
80. Xu Q, Dietrich H, Steiner HJ, Gown AM, Schoel B, Mikuz G, Kaufmann SH, Wick G Induction of arteriosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65. Arterioscler Thromb 1992, 12:789-799.
81. Pockley AG, Wu R, Lemne C, Kiessling R, de Faire U, Frostegard J Circulating heat shock protein 60 is associated with early cardiovascular disease. Hypertension 2000, 36:303-307.
82. Pockley AG, De Faire U, Kiessling R, Lemne C, Thulin T, Frostegard J Circulating heat shock protein and heat shock protein antibody levels in established hypertension. J Hypertens 2002, 20:1815-1820.
83. Frostegard J, Lemne C, Andersson B, van der Zee R, Kiessling R, de Faire U Association of serum antibodies to heat-shock protein 65 with borderline hypertension. Hypertension 1997, 29:40-44.
84. Xu Q, Willeit J, Marosi M, Kleindienst R, Oberhollenzer F, Kiechl S, Stulnig T, Luef G, Wick G Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis. Lancet 1993, 341:255-259.
85. Pockley AG, Georgiades A, Thulin T, De Faire U, Frostegard J Serum Heat Shock Protein 70 Levels Predict the Development of Atherosclerosis in Subjects With Established Hypertension. Hypertension 2003, 42:235-238.